Immunome stock gets FDA clearance for fifth clinical program
Immunome (IMNM) received FDA clearance for its Investigational New Drug application for IM-1340, an antibody-drug conjugate targeting advanced solid tumors, marking its fifth clinical program. The company expects to begin a Phase 1 study in Q4 2026. Despite a recent Q2 loss exceeding estimates, the stock's consensus target remains significantly above its current Nasdaq price, with the next earnings report scheduled for November 16, 2026.
Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed?
Immunome's stock dropped 6.5% after the FDA cleared its Investigational New Drug (IND) application for IM-1340, a novel antibody-drug conjugate for advanced solid tumors, allowing Phase 1 trials to begin. This development adds another oncology candidate to Immunome's pipeline, reinforcing its focus on both its potential first commercial product, varegacestat, and its growing ADC platform. The company's investment narrative still heavily relies on varegacestat's PDUFA decision, with forecasts projecting significant revenue and earnings growth by 2029.
Immunome (IMNM) Stock May Be A Bargain After IM 1340 Clearance
Immunome (IMNM) has seen a strong 178.2% return over the past 3 years, and recent FDA clearance for its IM-1340 IND has sparked investor interest in its potential cash flows. Despite current negative free cash flow, a Discounted Cash Flow (DCF) analysis suggests the stock may be modestly undervalued compared to its current share price of $20.89, with future cash generation tied to its pipeline development. The article emphasizes evaluating the company's valuation through its potential future cash flows, especially following the IM-1340 clearance, and highlights community narratives suggesting it could be significantly undervalued.
Immunome gains FDA IND clearance for IM‑1340 solid tumour study
Immunome Inc. (NASDAQ: IMNM) has received FDA IND clearance for its experimental cancer drug IM-1340, allowing it to proceed with a Phase 1 human study in the fourth quarter of 2026 for advanced solid tumors. This antibody-drug conjugate (ADC) targets a transport receptor expressed in various tumors and is the company's fifth program in clinical development. Immunome, a targeted oncology developer, reported cash and equivalents of US$520 million as of June 30, 2026, projected to fund operations into 2028.
Stifel initiates Immunome stock coverage with Hold rating at $24 By Investing.com
Stifel has initiated coverage on Immunome Inc. (NASDAQ:IMNM) with a "Hold" rating and a price target of $24.00, noting that the stock currently trades below this target but has shown an 87% return over the past year. The firm highlighted concerns about Immunome's varegacestat, currently under FDA review, and the platform risks associated with its antibody-drug conjugate pipeline and radioligand therapy. Despite these concerns, Immunome maintains a strong market cap and liquidity to support its pipeline.
Immunome receives FDA clearance for IM-1340 solid tumor trial By Investing.com
Immunome Inc. (NASDAQ:IMNM) has received FDA clearance for its Investigational New Drug (IND) application for IM-1340, an antibody-drug conjugate for advanced solid tumors. The company plans to start a Phase 1 study in Q4 2026, marking IM-1340 as Immunome's fifth clinical-stage program. The therapy targets a transport receptor found in various solid tumors and has shown promising anti-tumor activity in preclinical studies.
Immunome receives FDA clearance for IM-1340 solid tumor trial
Immunome Inc. has received FDA clearance for its Investigational New Drug application for IM-1340, an antibody-drug conjugate designed to treat advanced solid tumors. The company plans to begin a Phase 1 study in Q4 2026, marking IM-1340 as Immunome's fifth clinical development program. This investigational therapy targets a transport receptor found across various solid tumors and has shown promising anti-tumor activity in preclinical studies.
A. G. P. Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $32
A. G. P. has initiated coverage on Immunome (IMNM.US) with a "Buy" rating. The firm has set a target price of $32 for Immunome's stock. This indicates a positive outlook from A. G. P. regarding Immunome's future performance.
(IMNM) Risk Channels and Responsive Allocation
This article analyzes Immunome Inc. (NASDAQ: IMNM) using AI models, identifying divergent sentiment and a mid-channel oscillation pattern. It presents three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored to different risk profiles, along with multi-timeframe signal analysis and specific entry/target/stop loss levels. The analysis highlights an exceptional risk-reward short setup.
Immunome, Inc. (IMNM) Stock Analysis: Exploring a 51.72% Potential Upside in Biotechnology
Immunome, Inc. (IMNM) shows significant growth potential in the biotechnology sector, driven by its innovative pipeline in antibody-drug conjugates and oncology therapeutics. Despite current financial challenges typical of early-stage biotech firms, analysts project a 51.72% potential upside with strong buy ratings. Investors are advised to weigh the inherent risks against the promising future returns as the company advances its clinical trials.
Immunome CSO Higgins Jack Executes 18,000 Options at $1.35, Sells and Gifts Shares (NASDAQ: IMNM)
Immunome Inc.'s Chief Scientific Officer, Higgins Jack, exercised options for 18,000 shares at $1.35 each on September 11, 2026. On the same day, he sold 13,200 shares at $25.32 per share and gifted 8,800 shares. These transactions adjusted his reported holdings to 56,250 shares and 133,840 derivative securities.
Immunome at H.C. Wainwright conference: pipeline bets on ADCs By Investing.com
Immunome presented its two-part strategy at the H.C. Wainwright 28th Annual Global Investment Conference, focusing on the near-term approval of varegacestat for desmoid tumors and a long-term plan to build an antibody-drug conjugate (ADC) franchise. The company highlighted clinical progress and a large pipeline, emphasizing its proprietary HC74 Topo1 payload technology designed to overcome historical ADC weaknesses. CEO Clay Siegall stressed the importance of differentiated efficacy for their lead ADC program, IM-1021, and discussed the strategic commercialization of varegacestat.
Immunome at H.C. Wainwright conference: pipeline bets on ADCs By Investing.com
Immunome presented its two-part strategy at the H.C. Wainwright 28th Annual Global Investment Conference, focusing on near-term approval for varegacestat in desmoid tumors and building a broad antibody-drug conjugate (ADC) franchise. The company aims for differentiated efficacy with its lead ADC program, IM-1021, targeting heavily pretreated B-cell lymphoma, and is developing at least 10 novel ADCs using its proprietary HC74 Topo1 payload technology designed to overcome historical ADC limitations.
Immunome, Inc. Revenue Breakdown – NASDAQ:IMNM
Immunome, Inc. (NASDAQ:IMNM) generated $6.94 million in revenue last year, primarily from its Targeted Oncology Therapies segment. This marks a decrease from the previous year's revenue of $9.04 million. The United States was the sole geographic contributor to this revenue.
Planned sale of 13,200 Immunome (NASDAQ: IMNM) shares disclosed in Rule 144 notice
Jack P. Higgins plans to sell 13,200 Immunome (NASDAQ: IMNM) common shares, valued at approximately $334,224, through Fidelity Brokerage Services LLC under Rule 144. These shares were acquired via a stock option exercise on September 10, 2025. The filing indicates that 113,577,629 common shares of Immunome are outstanding.
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Immunome, Inc., a clinical-stage targeted oncology company, announced that its management will present at H.C. Wainwright's 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET. The presentation will be available via live audio webcast on the company's investor relations website, with a replay available for approximately 30 days afterward. The company is focused on developing first-in-class and best-in-class targeted cancer therapies.
Immunome (IMNM) Reports A Wider Loss, Is The Premium Valuation Justified?
Immunome (IMNM) reported a wider loss in Q2 2026, leading to questions about its premium valuation. Despite a 182.36% one-year total shareholder return, the company's P/B ratio of 6.1x is higher than peers and the industry average, suggesting it might be overvalued based on current financials. However, a Simply Wall St Discounted Cash Flow (DCF) model estimates a fair value of $115.29, indicating potential undervaluation if future cash flows are considered.
Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors?
Immunome, Inc. (IMNM) recently reported increased net losses and loss per share for the second quarter and first half of 2026. Concurrently, the company filed a US$38.54 million shelf registration for 1,500,000 common shares related to an employee stock ownership plan. These developments highlight the company's funding-intensive nature, raising questions for investors about funding and potential share dilution despite the company's oncology platform and pipeline.
Immunome Stock Up 32% in a Month: Here's What You Should Know
Immunome (IMNM) has seen a 31.6% stock increase in the past month, driven by investor confidence in its lead asset, varegacestat, and broader clinical progress. The FDA has accepted Immunome's new drug application for varegacestat for desmoid tumors, with a decision expected by April 28, 2027. The company is also advancing other pipeline candidates, including IM-1021 and antibody-drug conjugates, indicating strong long-term growth potential.
Enterprise value to revenue forward of Immunome, Inc. – NASDAQ:IMNM
This article focuses on the enterprise value to revenue forward for Immunome, Inc. (NASDAQ:IMNM). It appears to be a financial data snippet from TradingView, highlighting a specific financial metric for the biotechnology company. The content itself is minimal, primarily indicating the existence of this data point.
Bank of America Corp DE Boosts Stake in Immunome, Inc. $IMNM
Bank of America Corp DE significantly increased its stake in Immunome, Inc. (NASDAQ:IMNM) by 285.6% during the first quarter, now owning 781,607 shares valued at over $17 million. This move is part of broader institutional investor activity, with several hedge funds adjusting their positions in the company. Immunome, a clinical-stage biotechnology firm, has also seen recent insider selling and varying analyst ratings, with an average "Moderate Buy" rating and a price target of $34.64.
Immunome (NASDAQ:IMNM) Sets New 12-Month High - Should You Buy?
Immunome (NASDAQ:IMNM) recently hit a new 52-week high of $29, with a market capitalization of $3.38 billion, despite missing quarterly earnings expectations. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and a $34.64 price target, though insiders have been selling shares while institutional investors hold 44.58% of the stock. The company is a clinical-stage biotechnology firm focused on developing antibody-based therapeutics for oncology and infectious diseases.
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration
Immunome (IMNM) is facing investor scrutiny after reporting wider net losses and filing a shelf registration, despite a significant 1-year stock return of 173.45%. The company's valuation presents conflicting signals, with a Price-to-Book ratio of 5.9x suggesting overvaluation compared to peers, while a Discounted Cash Flow model indicates it's trading 76.3% below its estimated fair value. Investors are left to weigh high growth expectations against increased loss and potential dilution.
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration
Immunome (IMNM) is facing a valuation test after reporting wider net losses and filing a new shelf registration to issue more shares, despite a significant stock price increase over the last year. The company's P/B ratio of 5.9x is higher than peers, suggesting investors are betting on its oncology pipeline rather than current earnings, while a DCF model indicates the stock is undervalued. This mixed outlook highlights the need for investors to carefully review underlying data and consider both the potential upside and warning signs.
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts
Immunome, Inc. (NASDAQ:IMNM) has received an average "Moderate Buy" rating from analysts, with a 12-month average price target of $34.64. Despite this positive outlook, the company missed its quarterly earnings estimates and experienced significant insider selling totaling $15.7 million over the past three months. Institutional investors currently own 44.58% of the stock.
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story?
Immunome, Inc. (IMNM) was removed from several Russell indices in late June 2026, coinciding with insider stock sales. This exit is expected to significantly impact the company's shareholder base and trading liquidity, making future funding for its pipeline more sensitive to market fluctuations. Despite recent stock price increases, the company faces substantial annual losses and no clear path to profitability, with analyst fair value estimates showing wide disagreement.
Immunome director Isaac Barchas sells $940,453 in common stock
Immunome director Isaac Barchas sold $940,453 worth of the company's common stock in early August 2026 through two transactions executed via a Rule 10b5-1 trading plan. The sales occurred when the stock was trading near its 52-week high, despite an InvestingPro analysis indicating the stock remains undervalued. Mr. Barchas disclaimed beneficial ownership except for his pecuniary interest in the shares, which are held indirectly by AMBHMC II LLC, where he is a managing member.
Dimensional Fund Advisors LP Decreases Stock Position in Immunome, Inc. $IMNM
Dimensional Fund Advisors LP significantly reduced its stake in Immunome, Inc. (NASDAQ:IMNM) by 89.4% in the first quarter, selling 282,975 shares and retaining 33,408 shares valued at $731,000. Despite this reduction and recent insider selling totaling $15.7 million, institutional investors still hold 44.58% of the company. Immunome reported a quarterly loss of $0.65 per share, missing analyst estimates, yet analysts generally maintain a "Moderate Buy" rating with a consensus price target of $34.64.
Immunome (IMNM) Is Up 8.7% After Wider Loss And ESOP Shelf Filing What’s Changed
Immunome (IMNM) shares rose by 8.7% despite the company reporting a wider net loss and increased loss per share for Q2 and the first half of 2026. The biotech firm also filed a US$38.54 million shelf registration for an ESOP-related offering, aiming to maintain financial flexibility for future capital needs. The company's investment narrative continues to center on its desmoid tumor candidate, varegacestat, and early ADC pipeline, with a PDUFA date for varegacestat set for April 2027.
Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Immunome (NASDAQ:IMNM) to a "strong sell" rating, contrasting with the broader analyst consensus of "Moderate Buy" and a price target of $34.64. This downgrade follows Immunome reporting a quarterly loss of $0.65 per share, missing estimates, with full-year losses expected around $2.30 per share. Insider selling has also occurred, with approximately $15.7 million worth of shares sold by company insiders over the past three months.
T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5%
T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 17.4% of Immunome, Inc. common stock, totaling 19,676,883 shares, according to a recent SEC filing. The firm holds sole voting power over 19,656,814 shares and sole dispositive power over all 19,676,883 shares. Additionally, its T. Rowe Price Small-Cap Stock Fund holds a 6.5% interest in Immunome, representing 7,179,563 shares.
Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A
Sirenia Capital Management LP and Alex Silverstein have reported a 4.3% beneficial ownership stake in Immunome Inc. (IMNM) through an amended Schedule 13G filing. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the 113,250,394 shares outstanding as of May 7, 2026. The reporting persons have shared voting and dispositive power over these shares, and the filing indicates their stake is below the 5% threshold.
Renaissance Technologies LLC Makes New Investment in Immunome, Inc. $IMNM
Renaissance Technologies LLC has acquired a new stake in Immunome, Inc. (NASDAQ:IMNM), purchasing over 68,000 shares worth approximately $1.5 million. This investment comes as other institutional investors have also increased their holdings in the clinical-stage biotechnology company, which recently reported a wider-than-expected quarterly loss of $0.65 per share. Despite the loss, analyst sentiment remains largely positive, with a "Moderate Buy" rating and an average price target of $34.64.
Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade
Immunome (NASDAQ:IMNM) shares hit a new 52-week high of $28.04 after Truist Financial raised its price target to $38 from $37, maintaining a "Buy" rating. Despite a larger-than-expected quarterly loss and significant insider selling, analyst sentiment remains largely positive, with a consensus price target of $34.64. The company’s stock closed at $27.99, up from its previous close of $26.25, reflecting investor confidence following the analyst upgrade and progress in its clinical-stage antibody programs.
Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027
Immunome is advancing varegacestat for desmoid tumors after its Phase 3 RINGSIDE study showed an 84% reduction in disease progression or death risk. The FDA has accepted the New Drug Application with a target action date of April 28, 2027, and the company plans to seek approval in Europe by the end of 2026. Immunome is also expanding its oncology pipeline with three additional clinical-stage programs enrolling patients.
Immunome director Isaac Barchas sells over $2.1m in shares By Investing.com
Immunome director Isaac Barchas sold over $2.19 million worth of company shares in August 2026 through pre-arranged Rule 10b5-1 trading plans. These sales included shares held indirectly by AMBHMC II LLC and directly by Barchas, following which he directly holds 92,211 shares. The sales occurred as Immunome's stock is near its 52-week high, despite an InvestingPro analysis suggesting it remains undervalued.
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares
Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 11,048 shares of the company's stock for over $301,000, reducing his holdings by 10.7%. This sale is part of a series of transactions under a pre-arranged trading plan, totaling about $2.6 million from August 10-12. Despite the sales and Immunome missing its quarterly earnings estimates, analysts maintain a "Moderate Buy" rating with an average price target of $34.64.
Immunome, Inc. Stock 12‑Month Price Target Raised to $36.31, Implies 38% Upside
Immunome, Inc.'s average 12-month price target has been increased to $36.31 by 13 analysts, up from $35.77, with individual forecasts ranging from $30 to $40 per share. This new target suggests a potential upside of approximately 38% from its August 11 closing price. The consensus rating for Immunome, Inc. remains a "Buy" among 14 analysts.
Immunome stock hits 52-week high at 27.68 USD
Immunome Inc. (IMNM) stock has reached a new 52-week high of $27.68, reflecting significant investor confidence with a 1-year change of 175.42%. Despite InvestingPro analysis suggesting the shares may be overvalued, analysts have revised earnings upwards, with price targets ranging from $30 to $40. Recent company developments, including initiating Phase 1 trials for IM-3050 and IM-1617 and the FDA's acceptance of a New Drug Application for varegacestat, indicate ongoing progress in its therapeutic advancements.
Immunome Inc. SEC Filing (Aug 12, 2026)
This article reports on an Immunome Inc. SEC Filing (Form 144) submitted on August 12, 2026, which details a proposed sale of 11,048 shares of common stock with an aggregate market value of $301,058.00. The filing, accepted by the SEC EDGAR at 11:40 AM on that date, also provides information about the acquisition of these securities on March 30, 2026, as an investment distribution from the issuer.
Immunome Inc. Q2 2026: Revenue $0 Net loss $73.1M, EPS $(0.65) — 10-Q Summary
Immunome Inc. reported Q2 2026 financial results, showing zero revenue and a net loss of $73.1 million, or $(0.65) per diluted share. This is a decline compared to the prior year's Q2 2025, which had $4 million in revenue and a net loss of $43.4 million. The company announced progress in its clinical trials, an increase in R&D investment, and expects its cash reserves to fund operations for at least the next 12 months.
Immunome Inc. Q2 2026: Revenue $0 Net loss $73.1M, EPS $(0.65) — 10-Q Summary
Immunome Inc. reported Q2 2026 results with $0 revenue and a net loss of $73.1 million, or $(0.65) per diluted share, compared to $4 million revenue and a $43.4 million net loss in the prior-year quarter. Key business highlights include the FDA's acceptance of an NDA for varegacestat, clinical progress in multiple drug candidates, and increased R&D investment. The company expects its cash reserves to fund operations for at least 12 months.
Immunome director Isaac Barchas sells over $2.1m in shares
Immunome Inc. director Isaac Barchas sold over $2.1 million worth of company shares in early August 2026 through pre-arranged trading plans. These sales occurred as Immunome's stock traded near its 52-week high, following a significant 182% return over the past year. Despite the sales, an InvestingPro analysis suggests the stock remains undervalued relative to its fair value.
Immunome Q2 Results: EPS Misses Estimate, Losses Widen 30% YoY
Immunome Inc. reported a Q2 2026 net loss of $73.1 million, significantly wider than the previous year, primarily due to increased R&D and administrative expenses, and missed EPS estimates. Despite financial challenges, the company secured FDA acceptance for its varegacestat NDA with a PDUFA date of April 28, 2027, and advanced other oncology pipeline candidates. The company maintains a robust cash position of $520.0 million to fund operations into 2028.
Immunome (NASDAQ:IMNM) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS
Immunome (NASDAQ:IMNM) announced its quarterly earnings, reporting a loss of $0.65 per share, which missed the consensus estimate by $0.14. Despite the earnings miss, the stock rose by $0.56 to $26.25, and analysts largely maintain a "Moderate Buy" rating with a $34.18 average price target. Insider transactions show significant sales, while institutional investors hold 44.58% of the company.
California State Teachers Retirement System Has $2.44 Million Stock Position in Immunome, Inc. $IMNM
The California State Teachers Retirement System significantly increased its stake in Immunome, Inc. by 66.3% in the first quarter, now holding 111,444 shares valued at $2.44 million. Despite recent insider selling, institutional investors collectively own 44.58% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $34.18. Immunome recently reported a better-than-expected quarterly loss and is trading at $25.69.
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Immunome, Inc. announced its second-quarter 2026 financial results, highlighting progress in its oncology pipeline. Key updates include the FDA acceptance of the NDA for varegacestat for desmoid tumors with a PDUFA target date of April 28, 2027, and the initiation of Phase 1 trials for IM-1617 (solid tumor ADC) and IM-3050 (FAP-targeted radioligand therapy). The company reported $520.0 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2028.
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 15,248 Shares
Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 15,248 shares of the company's stock on August 7th for over $397,000, reducing his direct holdings by 17.39%. This sale was part of a pre-arranged Rule 10b5-1 plan, and he has sold more than 320,000 shares since late June. Immunome's stock is trading near its 52-week high, and analysts maintain a "Moderate Buy" consensus with an average target price of $34.18.
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 20,840 Shares
Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 20,840 shares of the company's stock on August 6th at an average price of $26.06, totaling over $543,000. This transaction was part of a Rule 10b5-1 plan and reduced his holdings by 19.21%. This sale is one of several made by Barchas since late June, totaling more than 300,000 shares.
Price to sales forward of Immunome, Inc. – NASDAQ:IMNM
This article displays the "Price to sales forward" metric for Immunome, Inc. (NASDAQ: IMNM) on TradingView. It presents financial data for the company, indicating the value, change, and percentage change for this specific financial ratio. The content is primarily a data point rather than an in-depth analysis.
